Oncopharmpod
Repotrectinib & Capivasertib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:23:49
- More information
Informações:
Synopsis
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
